India · Delayed Price · Currency is INR Mankind Pharma Statistics
Total Valuation
Mankind Pharma has a market cap or net worth of INR 1.03 trillion. The enterprise value is 1.06 trillion.
| Market Cap | 1.03T |
| Enterprise Value | 1.06T |
Important Dates
The last earnings date was Monday, October 26, 2026.
| Earnings Date | Oct 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 413.05M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.67% |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | 57.67% |
| Owned by Institutions (%) | 20.71% |
| Float | 113.08M |
Valuation Ratios
The trailing PE ratio is 45.79 and the forward PE ratio is 38.24.
| PE Ratio | 45.79 |
| Forward PE | 38.24 |
| PS Ratio | 6.69 |
| PB Ratio | 5.76 |
| P/TBV Ratio | 58.26 |
| P/FCF Ratio | 40.51 |
| P/OCF Ratio | 31.14 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 25.63, with an EV/FCF ratio of 41.70.
| EV / Earnings | 47.21 |
| EV / Sales | 6.89 |
| EV / EBITDA | 25.63 |
| EV / EBIT | 32.37 |
| EV / FCF | 41.70 |
Financial Position
The company has a current ratio of 1.35, with a Debt / Equity ratio of 0.30.
| Current Ratio | 1.35 |
| Quick Ratio | 0.82 |
| Debt / Equity | 0.30 |
| Debt / EBITDA | 1.32 |
| Debt / FCF | 2.14 |
| Interest Coverage | 6.41 |
Financial Efficiency
Return on equity (ROE) is 13.56% and return on invested capital (ROIC) is 12.46%.
| Return on Equity (ROE) | 13.56% |
| Return on Assets (ROA) | 7.05% |
| Return on Invested Capital (ROIC) | 12.46% |
| Return on Capital Employed (ROCE) | 14.12% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 7.52M |
| Profits Per Employee | 1.10M |
| Employee Count | 20,451 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 2.06 |
Taxes
In the past 12 months, Mankind Pharma has paid 6.03 billion in taxes.
| Income Tax | 6.03B |
| Effective Tax Rate | 21.04% |
Stock Price Statistics
The stock price has increased by +2.85% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +2.85% |
| 50-Day Moving Average | 2,377.27 |
| 200-Day Moving Average | 2,310.47 |
| Relative Strength Index (RSI) | 58.68 |
| Average Volume (20 Days) | 68,326 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Mankind Pharma had revenue of INR 153.79 billion and earned 22.43 billion in profits. Earnings per share was 54.24.
| Revenue | 153.79B |
| Gross Profit | 109.27B |
| Operating Income | 32.58B |
| Pretax Income | 28.67B |
| Net Income | 22.43B |
| EBITDA | 40.89B |
| EBIT | 32.58B |
| Earnings Per Share (EPS) | 54.24 |
Balance Sheet
The company has 26.60 billion in cash and 54.22 billion in debt, with a net cash position of -27.61 billion.
| Cash & Cash Equivalents | 26.60B |
| Total Debt | 54.22B |
| Net Cash | -27.61B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 178.55B |
| Book Value Per Share | 425.79 |
| Working Capital | 20.71B |
Cash Flow
In the last 12 months, operating cash flow was 33.03 billion and capital expenditures -7.64 billion, giving a free cash flow of 25.39 billion.
| Operating Cash Flow | 33.03B |
| Capital Expenditures | -7.64B |
| Depreciation & Amortization | 8.32B |
| Net Borrowing | -29.12B |
| Free Cash Flow | 25.39B |
| FCF Per Share | n/a |
Margins
Gross margin is 71.05%, with operating and profit margins of 21.18% and 14.58%.
| Gross Margin | 71.05% |
| Operating Margin | 21.18% |
| Pretax Margin | 18.64% |
| Profit Margin | 14.58% |
| EBITDA Margin | 26.59% |
| EBIT Margin | 21.18% |
| FCF Margin | 16.51% |
Dividends & Yields
Mankind Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.67% |
| Shareholder Yield | -0.67% |
| Earnings Yield | 2.18% |
| FCF Yield | 2.47% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Mankind Pharma is 2,703.26, which is 8.84% higher than the current price. The consensus rating is "Buy".
| Price Target | 2,703.26 |
| Price Target Difference | 8.84% |
| Analyst Consensus | Buy |
| Analyst Count | 19 |
| Revenue Growth Forecast (3Y) | 12.87% |
| EPS Growth Forecast (3Y) | 18.41% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 7 |